The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

February 1, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists will still use drugs like cyclophosphamide to treat aggressive lupus despite their potential toxicity, she concluded. Elevated lymphoma risk in SLE is still relatively low, she added.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
Explore This Issue
February 2013
Also By This Author
  • 2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases

Hypertension in SLE Patients

In her presentation, Hong Fang, MD, professor of medicine at the Johns Hopkins University School of Medicine in Baltimore, explored poorly controlled hypertension in SLE patients. People with lupus have a 2.66-fold increased risk for cardiovascular events like stroke, poor renal outcome, and coronary artery disease compared with the general population, she said. Achieving better hypertension control in patients with SLE may improve those rates, she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a recent study based on the Hopkins Lupus Cohort, Dr. Fang and her colleagues found that 1,655 out of 2,209 SLE patients had hypertension during participation, defined as a systolic blood pressure equal to or greater than 140 mm Hg, diastolic blood pressure equal to or greater than 90 mm Hg, or the use of any hypertensive medication.

Patients with hypertension were more likely to be older, male, African-American, have a higher body mass index, and have less education, she said. Higher disease activity plays a role, as well as a higher urine protein-to-creatinine ratio and average serum creatinine, she said. Prednisone use was also associated with higher hypertension rates.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Only 9% of patients in the study met the goal of reaching a systolic blood pressure of less than 120 mm, Dr. Fang said. Interventions like working with patients to reduce weight and prescribing hydroxychloroquine may reverse that trend, she added, even though the mechanism for why hydroxychloroquine is associated with less hypertension is still not understood.

Looking at Molecular Signatures in Lupus

In her presentation, Meggan Mackay, MD, MS, a researcher at the Feinstein Institute for Medical Research in Manhasset, N.Y., spoke about molecular signatures in lupus, differentiating patients dealing with inflammation from those grappling with an infection. SLE patients are more susceptible to serious infections due to both their disease and the immunosuppressant drugs used to treat it, Dr. Mackay said.

Dr. Mackay and her colleagues sought to utilize RNA microarray blood analysis to identify specific profiles that would differentiate a response to systemic inflammation and infection in acutely ill, hospitalized lupus patients. Three groups were studied—27 ill patients hospitalized with a suspected infection, 16 with stable lupus and no evidence of disease activity, and 20 healthy individuals. For all three groups, three milliliters of whole blood was taken over three days; a total of 239 whole blood specimens were taken across six clinical conditions, including flare and infection, and controls.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: comorbidities, Lupus, Research, SLE, TreatmentIssue: February 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • 2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)